Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 3Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 71Gastrointestinal 43Head & Neck 30Breast 25Genitourinary 19Other solid neoplasm 17Gynecologic 17Sarcoma 10Lymphoid 9Dermatologic 6Tumor-Agnostic 4CNS 4Plasma cell 3Other hematologic neoplasm 2Endocrine 2NET 1Myeloid 1

Conditions

Multiple Myeloma 3Recurrence 2

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × durvalumab × Plasma cell × Clear all
NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Celgene

Phase 1 Completed
114 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Celgene

Phase 1/2 Completed
56 enrolled 38 charts
Plasma cell

Multiple Myeloma

NCT03000452 2018-10-16

FUSION-MM-005

Celgene

Phase 2 Completed
18 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡